Olivier Brandicourt, M.D., is President and General Manager of the Emerging Markets and Established Products Business Units. He has 25 years of international experience in the pharmaceutical industry including executive responsibilities in France, the United States, Canada and the United Kingdom. He has held senior operational positions at Pfizer and previously held positions across a range of disciplines including medical and marketing with Warner-Lambert/Parke-Davis.
Until recently Olivier was President and General Manager of the Primary Care Business Unit and co-chaired the company's Portfolio Strategy and Investment (PSI) Committee which focuses on maximizing the return on R&D investment across the Pfizer Inc portfolio. Also he led the creation of the Integrated Health Business Unit focused on improving patient outcomes.
Before that, Olivier started the Specialty Care Business Unit and co-led the efforts to strengthen Pfizer's innovative core through Project ESI (Engine for Sustainable Innovation) launched in 2010. Most recently, he transitioned Lipitor, the industry's most significant medicine and one that he launched, from Pfizer's Primary Care business to the Established Products Business Unit, where it has demonstrated ongoing strong performance in its post-LOE period in the U.S.
Olivier holds a medical degree with a subspecialty in infectious diseases and Tropical Medicine, as well as a master's degree in biology from Paris University. After completing his studies, Olivier spent two years in the Congo as a doctor and eight years with the tropical disease Institute in Paris Salpétrière Hospital, where he spent half his time in West and Central Africa working on malaria research. Olivier is an Honorary Fellow of the Royal College of Physicians in London, UK, and a member of the Children's Aid Society's Board of Trustees in New York.